` RAD (Radiopharm Theranostics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

R
RAD
vs
S
S&P/ASX 300

Over the past 12 months, RAD has underperformed S&P/ASX 300, delivering a return of -40% compared to the S&P/ASX 300's +10% growth.

Stocks Performance
RAD vs S&P/ASX 300

Loading
RAD
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
RAD vs S&P/ASX 300

Loading
RAD
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
RAD vs S&P/ASX 300

Loading
RAD
S&P/ASX 300
Add Stock

Competitors Performance
Radiopharm Theranostics Ltd vs Peers

S&P/ASX 300
RAD
ABBV
AMGN
GILD
VRTX
Add Stock

Radiopharm Theranostics Ltd
Glance View

Market Cap
46.2m AUD
Industry
Biotechnology

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.

RAD Intrinsic Value
Not Available
R
Back to Top